Why C4 Therapeutics Stock Crushed the Market on Monday

C4 Therapeutics (NASDAQ: CCCC) was not only one of the better-performing healthcare stocks on Monday, it was one of the big winners on the market, period. The company seemed to have a rocket strapped to its back, as its share price blasted more than 34% higher after an analyst upgraded his recommendation. This was on a day when the S&P 500 index rose yet nowhere near as precipitously; it closed 0.5% in positive territory. That morning before the stock markets opened for business, Stephens prognosticator Sudan Loganathan made that upgrade. He's now a C4 bull, as he tagged the company as an overweight (read: buy) where previously he felt it only rated an equal weight (hold). His price target is now $6 per share, which is nearly double the current level of the shares. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool